Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
DOI
PMC
 |
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Inkretine als Grundlage der Adipositastherapie.
Incretins as the basis of obesity treatment.
Innere Med. 66, 461-466 (2025)
Obesity represents an immense challenge for patients and physicians due to its numerous comorbidities and complications. For a long time, safe and effective pharmacological treatment remained wishful thinking. Bariatric surgery was considered the only option for sustained weight loss; however, with the advent of incretin-based treatment, initially introduced as a highly effective component of anti-diabetic treatment, research began to focus on the complex gastroenteropancreatic endocrine system, including central hunger and satiety regulation. This shift was driven by the discovery of a remarkable side effect: placebo-controlled weight reduction. Subsequent groundbreaking pharmacological developments based on long-acting peptides, the administration of which could be reduced from twice daily in earlier forms of treatment to once weekly, now enables significant weight reduction of over 20%, with a tolerable safety profile. This article provides an illustrative overview of the corresponding associations and highlights this milestone in obesity treatment.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Appetite Regulation ; Glucagon-like Peptide 1 (glp-1) ; Glucose-dependent Insulinotropic Polypeptide (gip) ; Obesity/drug Therapy ; Weight Loss; Appetite
ISSN (print) / ISBN
2731-7080
e-ISSN
2731-7099
Zeitschrift
Innere Medizin
Quellenangaben
Band: 66,
Heft: 5,
Seiten: 461-466
Verlag
Springer
Verlagsort
Heidelbergerplatz 3, Berlin, Germany
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes and Obesity (IDO)